Eulogio
Conde García
Publikationen, an denen er mitarbeitet Eulogio Conde García (18)
2017
-
Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)
Annals of Hematology, Vol. 96, Núm. 8, pp. 1323-1330
-
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
Blood
-
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59
2014
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
-
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study
British Journal of Haematology, Vol. 164, Núm. 5, pp. 668-674
-
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis
Haematologica
2013
-
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group
Haematologica, Vol. 98, Núm. 10, pp. 1563-1570
2012
-
High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry
Biology of Blood and Marrow Transplantation, Vol. 18, Núm. 5, pp. 788-793
2009
-
Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas
Cancer, Vol. 115, Núm. 16, pp. 3728-3737
-
Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma
Leukemia and Lymphoma, Vol. 50, Núm. 4, pp. 571-581
2008
-
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group
European Journal of Haematology, Vol. 80, Núm. 3, pp. 227-235
2002
-
Myeloablative treatments for multiple myeloma: Update of a comparative study of different regimens used in patients from the Spanish Registry for transplantation in multiple myeloma
Leukemia and Lymphoma, Vol. 43, Núm. 1, pp. 67-74
2000
-
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
Hematology Journal, Vol. 1, Núm. 1, pp. 28-36
-
Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma
British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147
1997
-
Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: A retrospective study from the Spanish GEL-TAMO cooperative group
Bone Marrow Transplantation, Vol. 20, Núm. 4, pp. 283-288
1994
-
Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the spanish cooperative group GEL/TAMO
Bone Marrow Transplantation, Vol. 14, Núm. 2, pp. 279-286
1993
-
Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: A report from the Spanish GEL/TAMO Cooperative Group
Annals of Hematology, Vol. 67, Núm. 3, pp. 111-114
1992
-
Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy
Bone Marrow Transplantation, Vol. 10, Núm. 1, pp. 33-38